2029 Pharmaceuticals Vaccine Virus 
Drug Discovery World
JANUARY 9, 2024
Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The first approvals of RSV vaccines (RSVpreF and RSVpreF3) targeted at infants and older adults mark a significant public health milestone.
Drug Discovery World
OCTOBER 4, 2022
BV-101 is an adeno- associated virus (AAV) gene therapy vector that simultaneously addresses the metabolic dysfunction of diseased neurons and contributes to the clearance of the mutant huntingtin protein. The psychedelics medicine market is rising in value, with Data Bridge Market Research predicting it will reach $8 billion by 2029.
Expert insights. Personalized for you.
173 
Let's personalize your content